Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex

Plus: Longboard triples on strength of anticonvulsive readout and updates from Anavex, Roche-MediLink, Allorion-AstraZeneca and more

Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more  

Even with miscalculations and marginally positive data, investors see potential in blarcamesine findings

BioCentury’s roundup of translational news

Setbacks for HTT-targeting programs have put alternative therapeutic approaches out in front

Over half of clinical programs targeting muscarinic receptors for neuropsychiatric symptoms act on specific receptor subtypes

DISEASE CATEGORY: Endocrine/metabolic
INDICATION: Diabetes Dextromethorphan derivatives with reduced blood-brain barrier penetration could treat Type II diabetes without the CNS side effects

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the